While cationic antimicrobial peptides (CAPs) are compelling candidates for antimicrobial therapy, their clinical development is largely hampered by their rapid and non-specific enzymatic degradation in physiological fluids. We have earlier de novo designed and synthesized a novel category of CAPs typified by the sequence KKKKKK-AAFAAWAAFAA-NH2 (termed "6K-F17") that have remarkable membrane-penetrating power, are highly selective for bacterial rather than host membranes, and are non-cytotoxic. Here we pursue the design and validation of the Lys chain-shortened 6K-F17 analogs 6Dap-F17 (Dap = diaminopropionic acid), 6Dab-F17 (Dab = diaminobutyric acid), and 6Orn-F17 (Orn = ornithine). Intriguingly, although initially designed to specifically resist trypsin vs. their original Lys sites, all three derivatives of 6K-F17 showed markedly improved stability not only against trypsin, but also against the major proteolytic enzymes elastase and proteinase K at a 1:100 enzyme-to-peptide (E:P) ratio. When the least stable analog, 6Dap-F17, was then cyclized ('stapled') - with reduced main chain hydrophobicity to avoid erythrocyte hemolysis - the peptide became robust towards all three enzymes up to 60 min at a 1:100 E:P ratio, and retained strong presence even at an enhanced 1:1 E:P ratio, as determined by HPLC and mass spectrometry. These results suggest that the application of Lys chain-shortening, either alone or in combination with macrocyclization, may enhance metabolic stability of CAPs, and thus their clinical potential.